(Q45135279)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Gene expression analysis reveals functional pathways of glatiramer acetate activation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Vered Chalifa-Caspi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

3

Inbar Plaschkes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Shlomo Bakshi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Igor Perevozkin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Riki Schwartz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

8 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

351-362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

beadarray: R classes and methods for Illumina bead-based data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.778829

10.1517/14728222.2013.778829

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469939%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference